When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZN - Keytruda combo therapies show positive effects in prostate cancer study
AstraZeneca PLC
Preliminary data from an open-label Phase 1b/2 clinical trial, KEYNOTE-365, evaluating Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with various agents, in patients with metastatic castration-resistant prostate cancer (mCRPC) showed a treatment effect across three cohorts. The results are being presented at the ASCO GU Cancers Symposium in San Francisco.
More news on: Merck & Co Inc., AstraZeneca Group plc, Pfizer Inc., Healthcare stocks news,